A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer

[1]  G. Ball,et al.  Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis , 2021, Breast Cancer Research and Treatment.

[2]  Taobo Hu,et al.  Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores , 2021, BMC Medical Research Methodology.

[3]  F. De Amicis,et al.  Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma , 2020, Cells.

[4]  V. Kristensen,et al.  Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer , 2020, Breast Cancer Research and Treatment.

[5]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Ren,et al.  Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer , 2020, JAMA network open.

[7]  K. Goldberg,et al.  CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. , 2019, The Lancet. Oncology.

[8]  A. Lowery,et al.  Meta‐analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor‐positive breast cancer , 2019, The British journal of surgery.

[9]  Sung-Bae Kim,et al.  Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer , 2019, Breast Cancer Research and Treatment.

[10]  S. Andò,et al.  Progesterone Receptor B signaling Reduces Breast Cancer Cell Aggressiveness: Role of Cyclin-D1/Cdk4 Mediating Paxillin Phosphorylation , 2019, Cancers.

[11]  H. Sasano,et al.  Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[12]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[13]  Stephen B. Edge,et al.  Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer , 2018, Annals of Surgical Oncology.

[14]  R. Gelber,et al.  Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Fukutomi,et al.  Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions. , 2017, Biomedical reports.

[16]  R. Gelber,et al.  Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial , 2017, Annals of Surgical Oncology.

[17]  J. Lee,et al.  Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series , 2016, PloS one.

[18]  Sang‐wook Lee,et al.  Prognostic Factors for Distant Metastasis in Patients with Locoregional Recurrence after Mastectomy , 2015, Journal of breast cancer.

[19]  Rory Stark,et al.  Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.

[20]  Wonshik Han,et al.  Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence , 2015, Journal of breast cancer.

[21]  A. Taghian,et al.  Clinical outcome of isolated locoregional recurrence in patients with breast cancer according to their primary local treatment. , 2014, Clinical breast cancer.

[22]  A. Thompson,et al.  Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.

[23]  A. Luini,et al.  Breast cancer subtypes and outcome after local and regional relapse. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[25]  T. Osako,et al.  Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis , 2011, World journal of surgical oncology.

[26]  S. Tyldesley,et al.  Subsets of women with close or positive margins after breast-conserving surgery with high local recurrence risk despite breast plus boost radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[27]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[28]  J. Costantino,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Leung,et al.  Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients , 2009, Breast Cancer Research and Treatment.

[30]  Adrian V. Lee,et al.  Molecular profiles of progesterone receptor loss in human breast tumors , 2009, Breast Cancer Research and Treatment.

[31]  C. Geyer,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H Putter,et al.  Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. , 2006, European journal of cancer.

[33]  Adrian V. Lee,et al.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Adrian V. Lee,et al.  Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. , 2005, Journal of the National Cancer Institute.

[35]  A. Goldhirsch,et al.  Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Singletary,et al.  Classifying local disease recurrences after breast conservation therapy based on location and histology , 2002, Cancer.

[38]  W. Sauerbrei,et al.  Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Ronin,et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. , 1995, The New England journal of medicine.